Transforming AML Therapy: Lower-Intensity Regimens, Targeted Triplets, and Upfront Molecular Subtyping

Over the past decade, the acute myeloid leukemia (AML) treatment paradigm has evolved dramatically beyond traditional, highly intensive 7+3 induction chemotherapy, according to Daniel DeAngelo, MD, PhD, of Dana-Farber Cancer Institute. Historically reserved for older or unfit patients who could not tolerate intensive regimens, lower-intensity combinations combining a hypomethylating agent (HMA) with the BCL-2 inhibitor venetoclax (Venclexta) revolutionized upfront care.

Recent clinical data, including the landmark PARADIGM trial (NCT04801797) whose results were published in The New England Journal of Medicine, demonstrate that HMA plus venetoclax can be given in fit, younger patients with intermediate- or high-risk AML. In this population, excluding favorable-risk disease, lower-intensity therapy provides clinical efficacy comparable to or better than traditional intensive chemotherapy. This regimen yielded superior event-free control relative to standard cytarabine/anthracycline-based induction, results in significantly fewer infections, less time spent hospitalized, and reduced intensive care utilization, and serves as an enhanced bridge to allogeneic stem cell transplant. By minimizing treatment-related organ toxicity and infections, patients maintain a better performance status, enabling a higher proportion to successfully proceed to curative stem cell transplantation.

Building on this lower-intensity backbone, ongoing clinical trials are evaluating triplet combinations that add targeted agents to HMA plus venetoclax. Emerging paradigms investigate integrating FLT3 inhibitors for FLT3-mutated AML, IDH1/2 inhibitors for IDH-mutated disease, and menin inhibitors for NPM1-mutated or KMT2A-rearranged leukemias. Preliminary data confirm these targeted additions are well tolerated, with formal efficacy end points maturing.

Implementing these precision regimens requires a shift in diagnostic workflow. Although induction chemotherapy was historically initiated immediately, modern management demands rapid genomic and molecular subtyping before selecting therapy. DeAngelo says that clinicians should feel comfortable withholding therapy for a brief period to obtain comprehensive mutation panels. Taking the time to identify underlying driver mutations ensures every patient is matched to the most effective, personalized therapeutic strategy.